Table 1 summarizes the main clinical and laboratory findings. No significant differences in demographics, comorbidities, disease severity, organ involvement, or medication usage were observed between antibody-positive and antibody-negative patients. Similarly, there were no differences in serum positivity for other SLE-associated antibodies. Median levels of anti-Ro (0, 3–35 U/mL vs. 0, 0–108 U/mL; P = 0.47) and anti-Ro52 (0, 0–21 U/mL vs. 0, 0–97 U/mL; P = 0.86) antibodies were similar between the groups. The gene discussed is TRIM21; the disease is systemic lupus erythematosus.